To evaluate the efficacy and safety of switching from Infliximab to Golimumab in patients with Rheumatoid Arthritis

Trial Profile

To evaluate the efficacy and safety of switching from Infliximab to Golimumab in patients with Rheumatoid Arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Golimumab (Primary) ; Infliximab
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jan 2017 New trial record
    • 26 Dec 2016 Results published in the Drugs in R and D
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top